The acute pancreatitis market has grown strongly in recent years. It will grow from $5.56 billion in 2023 to $5.92 billion in 2024 at a compound annual growth rate (CAGR) of 6.6%. The rise observed in the historical period can be linked to elevated occurrence rates, alcohol consumption trends, prevalence of gallstones, habits of tobacco smoking, and escalating rates of obesity.
The acute pancreatitis market is expected to see strong growth in the next few years. It will grow to $7.41 billion in 2028 at a compound annual growth rate (CAGR) of 5.7%. The anticipated expansion during the forecasted period can be credited to trends in an aging population, initiatives promoting awareness and early diagnosis, studies on genetic predisposition, and advancements in treatment methods. Key forecasted trends encompass an emphasis on nutritional support, programs for patient education and awareness, the adoption of standardized protocols, exploration of regenerative therapies, and ongoing monitoring with follow-up procedures.
The anticipated surge in alcohol consumption is set to drive growth within the acute pancreatitis market. Consumption of ethanol-based beverages orally often leads to chronic inflammation and the production of harmful fluids in the pancreas. As the prevalence of alcohol consumption rises within populations, a consequent increase in acute pancreatitis cases is expected. Notably, figures from Rabobank in January 2022 revealed a significant spike in online alcohol sales, soaring from an estimated $441 million in 2019 to $1.6 billion in 2021. Furthermore, these sales continued to rise by approximately 15% in 2022, reaching $1.87 billion. Hence, the mounting prevalence of alcohol consumption acts as a driving force behind the acute pancreatitis market's growth.
The escalating incidence of obesity is poised to fuel the expansion of the acute pancreatitis market in the foreseeable future. Obesity, characterized by an excessive accumulation of body fat that poses health risks, is a known risk factor for acute pancreatitis. Its increasing global prevalence contributes to a higher incidence of this condition, thereby increasing the demand for related therapies. In March 2022, the World Health Organization reported a staggering figure of approximately 1 billion individuals worldwide - comprising 650 million adults, 340 million adolescents, and 39 million children - who were obese, with this number still on the rise. Additionally, WHO projections suggest that by 2025, 167 million adults and children will face health issues due to being overweight or obese. Thus, the mounting incidence of obesity serves as a key driver for the acute pancreatitis market.
The anticipated rise in gastrointestinal disorders is poised to be a driving factor behind the growth of the acute pancreatitis market in the forthcoming years. These disorders encompass a spectrum of medical issues affecting the gastrointestinal (GI) tract responsible for digestion and nutrient absorption. Conditions such as cholelithiasis, inflammatory bowel disease, and pancreatitis fall under this category, with pancreatitis often linked to or exacerbated by digestive system complications. This inflammation of the pancreas can be triggered by various factors, some of which are associated with the GI tract. For example, data from Crohn's and Colitis UK in March 2022 indicated that in the UK, one in 123 individuals suffers from ulcerative colitis, a type of inflammatory bowel disease known as Crohn's disease, totaling approximately 500,000 inflammatory bowel disease cases in the country. Hence, the increasing prevalence of gastrointestinal disorders is a significant driver fueling growth within the acute pancreatitis market.
A prominent trend gaining traction in the acute pancreatitis market involves technological advancements in diagnosis and treatment. Key companies operating within this market are embracing innovative technologies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP), and interventional radiology to maintain their market positions. For instance, in September 2021, Samsung Medison Co., Ltd., a South Korea-based manufacturer of diagnostic ultrasound machines, introduced the V8 - a high-end ultrasound device designed to provide enhanced image quality, user-friendliness, and convenience for medical practitioners across various specialties. The "V" designation in V8 denotes "Versatile," indicating the integration of sophisticated features typically found in high-end ultrasound systems catering to specialties such as radiology, orthopedics, cardiology, and obstetrics. Among its diagnostic capabilities, V8 incorporates S-Shearwave Imaging, utilizing ultrasound-based transverse elasticity to offer insights into tissue stiffness resulting from illness. Another feature, S-Fusion, facilitates the simultaneous alignment of ultrasound medical images with one or more cross-sectional investigations, such as MRIs, swiftly reconstructing them in the appropriate plane.
In January 2021, a partnership formed between Healx, a UK-based technology company leveraging AI to aid patients, and Mission, Cure, a US-based coalition comprising patients, caregivers, medical experts, academics, researchers, drug developers, and entrepreneurs. The collaboration aimed to pioneer the creation of the world's initial therapies targeting chronic pancreatitis. Mission, Cure is recognized for its innovative approach to funding outcome-focused research for treating various diseases.
Major companies operating in the acute pancreatitis market report are CalciMedica Inc., SCM Lifescience Co. Ltd., Samsung Bioepis Co Ltd., Global Neurotech Pharma Corporation, Baxter International Inc., B. Braun Melsungen AG, General Electric Company, Medtronic plc, Boston Scientific Corporation, Fresenius Kabi AG, McNeil Consumer Healthcare, Sun BioPharma Inc., Atox Bio Inc., D-Pharm Ltd., Regeneron Pharmaceuticals Inc., Merck & Co Inc., Olympus Corporation, Pfizer Inc., Ionis Pharmaceuticals Inc., Abbott Laboratories, Dynavax Technologies Corporation, GlaxoSmithKline plc, AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Novartis AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Johnson & Johnson,
North America was the largest region in the acute pancreatitis market in 2023. The regions covered in the acute pancreatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute pancreatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary causes of acute pancreatitis include gallstones, alcohol consumption, and other factors. Gallstones, which are solidified deposits in the gallbladder, can lead to pain and inflammation of the pancreas when they obstruct the pancreatic duct, resulting in acute pancreatitis. Treatment options for acute pancreatitis typically involve intravenous fluid administration, nutritional support, analgesics, and procedures such as endoscopic retrograde cholangiopancreatography (ERCP). The diagnosis of acute pancreatitis is carried out through imaging tests and laboratory assessments conducted by hospitals, clinics, and other healthcare facilities.
The acute pancreatitis market research report provides acute pancreatitis market statistics, including acute pancreatitis industry global market size, regional shares, competitors with a acute pancreatitis market share, detailed acute pancreatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the acute pancreatitis industry. This acute pancreatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute pancreatitis market includes revenues earned by entities by providing therapies, medications, and procedures aimed at managing and treating the condition. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The acute pancreatitis market is expected to see strong growth in the next few years. It will grow to $7.41 billion in 2028 at a compound annual growth rate (CAGR) of 5.7%. The anticipated expansion during the forecasted period can be credited to trends in an aging population, initiatives promoting awareness and early diagnosis, studies on genetic predisposition, and advancements in treatment methods. Key forecasted trends encompass an emphasis on nutritional support, programs for patient education and awareness, the adoption of standardized protocols, exploration of regenerative therapies, and ongoing monitoring with follow-up procedures.
The anticipated surge in alcohol consumption is set to drive growth within the acute pancreatitis market. Consumption of ethanol-based beverages orally often leads to chronic inflammation and the production of harmful fluids in the pancreas. As the prevalence of alcohol consumption rises within populations, a consequent increase in acute pancreatitis cases is expected. Notably, figures from Rabobank in January 2022 revealed a significant spike in online alcohol sales, soaring from an estimated $441 million in 2019 to $1.6 billion in 2021. Furthermore, these sales continued to rise by approximately 15% in 2022, reaching $1.87 billion. Hence, the mounting prevalence of alcohol consumption acts as a driving force behind the acute pancreatitis market's growth.
The escalating incidence of obesity is poised to fuel the expansion of the acute pancreatitis market in the foreseeable future. Obesity, characterized by an excessive accumulation of body fat that poses health risks, is a known risk factor for acute pancreatitis. Its increasing global prevalence contributes to a higher incidence of this condition, thereby increasing the demand for related therapies. In March 2022, the World Health Organization reported a staggering figure of approximately 1 billion individuals worldwide - comprising 650 million adults, 340 million adolescents, and 39 million children - who were obese, with this number still on the rise. Additionally, WHO projections suggest that by 2025, 167 million adults and children will face health issues due to being overweight or obese. Thus, the mounting incidence of obesity serves as a key driver for the acute pancreatitis market.
The anticipated rise in gastrointestinal disorders is poised to be a driving factor behind the growth of the acute pancreatitis market in the forthcoming years. These disorders encompass a spectrum of medical issues affecting the gastrointestinal (GI) tract responsible for digestion and nutrient absorption. Conditions such as cholelithiasis, inflammatory bowel disease, and pancreatitis fall under this category, with pancreatitis often linked to or exacerbated by digestive system complications. This inflammation of the pancreas can be triggered by various factors, some of which are associated with the GI tract. For example, data from Crohn's and Colitis UK in March 2022 indicated that in the UK, one in 123 individuals suffers from ulcerative colitis, a type of inflammatory bowel disease known as Crohn's disease, totaling approximately 500,000 inflammatory bowel disease cases in the country. Hence, the increasing prevalence of gastrointestinal disorders is a significant driver fueling growth within the acute pancreatitis market.
A prominent trend gaining traction in the acute pancreatitis market involves technological advancements in diagnosis and treatment. Key companies operating within this market are embracing innovative technologies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP), and interventional radiology to maintain their market positions. For instance, in September 2021, Samsung Medison Co., Ltd., a South Korea-based manufacturer of diagnostic ultrasound machines, introduced the V8 - a high-end ultrasound device designed to provide enhanced image quality, user-friendliness, and convenience for medical practitioners across various specialties. The "V" designation in V8 denotes "Versatile," indicating the integration of sophisticated features typically found in high-end ultrasound systems catering to specialties such as radiology, orthopedics, cardiology, and obstetrics. Among its diagnostic capabilities, V8 incorporates S-Shearwave Imaging, utilizing ultrasound-based transverse elasticity to offer insights into tissue stiffness resulting from illness. Another feature, S-Fusion, facilitates the simultaneous alignment of ultrasound medical images with one or more cross-sectional investigations, such as MRIs, swiftly reconstructing them in the appropriate plane.
In January 2021, a partnership formed between Healx, a UK-based technology company leveraging AI to aid patients, and Mission, Cure, a US-based coalition comprising patients, caregivers, medical experts, academics, researchers, drug developers, and entrepreneurs. The collaboration aimed to pioneer the creation of the world's initial therapies targeting chronic pancreatitis. Mission, Cure is recognized for its innovative approach to funding outcome-focused research for treating various diseases.
Major companies operating in the acute pancreatitis market report are CalciMedica Inc., SCM Lifescience Co. Ltd., Samsung Bioepis Co Ltd., Global Neurotech Pharma Corporation, Baxter International Inc., B. Braun Melsungen AG, General Electric Company, Medtronic plc, Boston Scientific Corporation, Fresenius Kabi AG, McNeil Consumer Healthcare, Sun BioPharma Inc., Atox Bio Inc., D-Pharm Ltd., Regeneron Pharmaceuticals Inc., Merck & Co Inc., Olympus Corporation, Pfizer Inc., Ionis Pharmaceuticals Inc., Abbott Laboratories, Dynavax Technologies Corporation, GlaxoSmithKline plc, AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Novartis AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Johnson & Johnson,
North America was the largest region in the acute pancreatitis market in 2023. The regions covered in the acute pancreatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute pancreatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary causes of acute pancreatitis include gallstones, alcohol consumption, and other factors. Gallstones, which are solidified deposits in the gallbladder, can lead to pain and inflammation of the pancreas when they obstruct the pancreatic duct, resulting in acute pancreatitis. Treatment options for acute pancreatitis typically involve intravenous fluid administration, nutritional support, analgesics, and procedures such as endoscopic retrograde cholangiopancreatography (ERCP). The diagnosis of acute pancreatitis is carried out through imaging tests and laboratory assessments conducted by hospitals, clinics, and other healthcare facilities.
The acute pancreatitis market research report provides acute pancreatitis market statistics, including acute pancreatitis industry global market size, regional shares, competitors with a acute pancreatitis market share, detailed acute pancreatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the acute pancreatitis industry. This acute pancreatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute pancreatitis market includes revenues earned by entities by providing therapies, medications, and procedures aimed at managing and treating the condition. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Acute Pancreatitis Market Characteristics3. Acute Pancreatitis Market Trends and Strategies31. Global Acute Pancreatitis Market Competitive Benchmarking32. Global Acute Pancreatitis Market Competitive Dashboard33. Key Mergers and Acquisitions in the Acute Pancreatitis Market
4. Acute Pancreatitis Market - Macro Economic Scenario
5. Global Acute Pancreatitis Market Size and Growth
6. Acute Pancreatitis Market Segmentation
7. Acute Pancreatitis Market Regional and Country Analysis
8. Asia-Pacific Acute Pancreatitis Market
9. China Acute Pancreatitis Market
10. India Acute Pancreatitis Market
11. Japan Acute Pancreatitis Market
12. Australia Acute Pancreatitis Market
13. Indonesia Acute Pancreatitis Market
14. South Korea Acute Pancreatitis Market
15. Western Europe Acute Pancreatitis Market
16. UK Acute Pancreatitis Market
17. Germany Acute Pancreatitis Market
18. France Acute Pancreatitis Market
19. Italy Acute Pancreatitis Market
20. Spain Acute Pancreatitis Market
21. Eastern Europe Acute Pancreatitis Market
22. Russia Acute Pancreatitis Market
23. North America Acute Pancreatitis Market
24. USA Acute Pancreatitis Market
25. Canada Acute Pancreatitis Market
26. South America Acute Pancreatitis Market
27. Brazil Acute Pancreatitis Market
28. Middle East Acute Pancreatitis Market
29. Africa Acute Pancreatitis Market
30. Acute Pancreatitis Market Competitive Landscape and Company Profiles
34. Acute Pancreatitis Market Future Outlook and Potential Analysis
35. Appendix
Executive Summary
This report provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on acute pancreatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for acute pancreatitis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Cause: Gallstones; Alcohol; Other Causes
2) By Treatment: Intravenous Fluid; Nutritional Support; Analgesics; Endoscopic Retrograde Cholangiopancreatography (ERCP); Other treatments
3) By Diagnosis: Imaging tests; Laboratory Tests
4) By End Users: Hospitals; Clinics; Other End-Users
Companies Mentioned: CalciMedica Inc.; SCM Lifescience Co. Ltd.; Samsung Bioepis Co Ltd.; Global Neurotech Pharma Corporation; Baxter International Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- CalciMedica Inc.
- SCM Lifescience Co. Ltd.
- Samsung Bioepis Co Ltd.
- Global Neurotech Pharma Corporation
- Baxter International Inc.
- B. Braun Melsungen AG
- General Electric Company
- Medtronic plc
- Boston Scientific Corporation
- Fresenius Kabi AG
- McNeil Consumer Healthcare
- Sun BioPharma Inc.
- Atox Bio Inc.
- D-Pharm Ltd.
- Regeneron Pharmaceuticals Inc.
- Merck & Co Inc
- Olympus Corporation
- Pfizer Inc.
- Ionis Pharmaceuticals Inc.
- Abbott Laboratories
- Dynavax Technologies Corporation
- GlaxoSmithKline plc
- AbbVie Inc.
- Allergan plc
- Amgen Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Novartis AG
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Incorporated
- Johnson & Johnson
